Qlife to follow up Danish clinical evaluation on rapid tests for covid-19
A Danish clinical evaluation on rapid tests for covid-19 conducted at Hvidovre Hospital was published on the Hospital’s website, 15 February 2022. The study includes a comparison of test results for SARS-CoV-2 with antigen tests compared with RT-qPCR. Results for Qlife's SARS-CoV-2 test differ from results published in previous peer-reviewed scientific studies on the test and the company has initiated a dialogue with Hvidovre Hospital.
"We are surprised that the results from the Danish clinical evaluation differ from previously scientific and published study on more than 1000 samples, which among others were conducted together with Hvidovre and Nordsjællands Hospital, on our SARS-CoV-2 test with the Egoo platform. We have contacted the study's lead author to get validate the evaluation method", says Thomas Warthoe, CEO of Qlife.
Previous scientific published study show that Qlife's covid-19 test can deliver test results with almost the same sensitivity and specificity as laboratory tests (qRT-PCR) in 30 minutes without access to specialized laboratory equipment.
Link to the report:
For more information please contact:
Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34
Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.
Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).
Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.